Clinical Trial: A Study to Assess the Safety, Tolerability and Pharmacokinetics of ABI-6250 in Participants With Mild Hepatic Impairment Compared With Participants With Normal Hepatic Function

U.S., Oct. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07850999) titled 'A Study to Assess the Safety, Tolerability and Pharmacokinetics of ABI-6250 in Participants With Mild Hepatic Impairment Compared With Participants With Normal Hepatic Function' on Sept. 14.

Brief Summary: This study is designed to assess the safety, tolerability and pharmacokinetics of ABI-6250 in participants with mild hepatic impairment compared with participants with normal hepatic function.

Study Start Date: Oct., 2026

Study Type: INTERVENTIONAL

Condition: Mild Hepatic Imparement

Intervention: DRUG: ABI-6250

Participants will receive ABI-6250 0.5 mg QD over 10 days.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Assemb...